Showing results (2071-2080 of 2,225) with videos related to

Sort By:
Pageof 223
Movement Disorders : Official Journal of the Movement Disorder Society|January 5, 2008
Phenotypic spectrum and sex effects in eleven myoclonus-dystonia families with epsilon-sarcoglycan mutationsDeborah Raymond, Rachel Saunders-Pullman, Patricia de Carvalho Aguiar, et al.
Physical Review Letters|April 12, 2006
Pinning frequencies of the collective modes in alpha-uraniumB Mihaila, C P Opeil, F R Drymiotis, et al.
Nature Medicine|June 18, 2013
Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugsErich Gulbins, Monica Palmada, Martin Reichel, et al.
Parkinsonism & Related Disorders|January 7, 2015
Helicobacter pylori infection is associated with worse severity of Parkinson's diseaseAi Huey Tan, Sanjiv Mahadeva, Connie Marras, et al.
Journal of Cancer Research and Clinical Oncology|November 19, 2020
PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern CaliforniaGino K In, Poorva Vaidya, Alexandra Filkins, et al.
Diabetes|November 4, 2018
Effects of Topically Administered Neuroprotective Drugs in Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical TrialRafael Simó, Cristina Hernández, Massimo Porta, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 30, 2014
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label resultsHubert H Fernandez, David G Standaert, Robert A Hauser, et al.
Biorxiv : the Preprint Server for Biology|October 9, 2023
4R-Tau seeding activity unravels molecular subtypes in patients with Progressive Supranuclear PalsyIvan Martinez-Valbuena, Seojin Lee, Enrique Santamaria, et al.
Geroscience|June 7, 2025
Subcortical white matter hyperintensities and motor function in parkinson's disease: findings from the ONDRI studyDaniela Cristina Carvalho de Abreu, Frederico Pieruccini-Faria, Anthony E Lang, et al.
Nature Medicine|August 13, 2021
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trialTien Dam, Adam L Boxer, Lawrence I Golbe, et al.
Pageof 223